By enhancing the stability and brain-targeting efficiency of the formulation, albumin-coated liposomes represent a significant advancement in the field of nanomedicine for neurodegenerative diseases, particularly in the treatment of PD. This evidence concerns the gene ALB and Parkinson disease.